Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren最新文献

Ovarian cancer remains a significant cause of mortality among women, largely due to challenges in early detection. Current screening strategies, including transvaginal ultrasound and CA125 testing, have limited sensitivity and specificity, particularly in asymptomatic women or those with early-stage disease. The European Society of Gynaecological Oncology, the European Society for Medical Oncology, the European Society of Pathology, and other health organizations currently do not recommend routine population-based screening for ovarian cancer due to the high rates of false-positives and the absence of a reliable early detection method.This review examines existing ovarian cancer screening guidelines and explores recent advances in diagnostic technologies including radiomics, artificial intelligence, point-of-care testing, and novel detection methods.Emerging technologies show promise with respect to improving ovarian cancer detection by enhancing sensitivity and specificity compared to traditional methods. Artificial intelligence and radiomics have potential for revolutionizing ovarian cancer screening by identifying subtle diagnostic patterns, while liquid biopsy-based approaches and cell-free DNA profiling enable tumor-specific biomarker detection. Minimally invasive methods, such as intrauterine lavage and salivary diagnostics, provide avenues for population-wide applicability. However, large-scale validation is required to establish these techniques as effective and reliable screening options. · Current ovarian cancer screening methods lack sensitivity and specificity for early-stage detection.. · Emerging technologies like artificial intelligence, radiomics, and liquid biopsy offer improved diagnostic accuracy.. · Large-scale clinical validation is required, particularly for baseline-risk populations.. · Chiu S, Staley H, Jeevananthan P et al. Ovarian Cancer Screening: Recommendations and Future Prospects. Rofo 2025; 197: 1395-1404.

To explore the peak enhancement time of a hepatocellular carcinoma, the pancreas, and the kidney cortex and its determinants.We obtained a time enhancement curve from the perfusion CT scans of 11 advanced HCC patients (40 volumes at 1.25 s time interval, slab slice 90 mm, bolus of 50 ml of iodinated contrast agent, 350 g iodine/ml, flow 5 ml/s). Small regions of interest were drawn on the abdominal aorta, the HCC, the cortex of the right kidney, and on the pancreas. The behavior of the contrast agent in the capillary and in the surrounding tissue was further explored with a finite element model.The peak enhancement time of the pancreas did not differ from that of the HCC (10±3 vs. 11±4 s, p=0.9), while the peak enhancement time of the kidney tended to be a few seconds earlier (8±1 s, p=0.082 vs. pancreas and p=0.069 vs. kidney). Simulation showed that the time span in which the tissue enhancement remained within 10% of its peak value was similar across all capillary densities and ranged between 26-38 s for a capillary density of 80 per mm to 30-60 s for a capillary density of 10.The plateau tissue enhancement clinically acquired in the "late arterial phase" should be adequate both for the detection of hypervascular liver lesions such as HCCs and for obtaining peak pancreatic enhancement to detect hypovascular lesions. · The peak tissue enhancement time of an HCC, the pancreas, and the kidney cortex is similar. · The tissue peak enhancement time in the arterial phase is at the end of bolus transit. · Simulation shows that tissue enhancement peak time is a function of capillary density. · Cressoni M, Cadringher P, Colarieti A et al. Is there a need for a CT scan of the pancreatic phase? A perfusion and simulation study of the pancreas, an HCC, and the kidney cortex. Rofo 2025; 197: 1405-1415.

Retrospective analysis of 245 consecutive cardiac CTA cases before and after transition from a 128-slice single-source CT scanner (SSCT, Definition AS+, temporal resolution 150ms, detector width 38.4mm) to a 128-slice dual-source CT scanner (DSCT, Pro.Pulse, 86ms, 38.4mm).A total of 113 patients (33f/80m, mean age 66.0 years) were examined using the SSCT scanner, while 132 patients (43f/89m, 64.7 years) were examined using the DSCT scanner. Protocol selection (sequential/spiral) was performed manually on the SSCT scanner. On the DSCT scanner, protocol selection was automated using built-in AI. Heart rate, kV for CTA, and DLP (mGy·cm) for CTA were recorded. Image quality was independently evaluated for the RCA, LM, LAD, and LCX by two experienced readers on a three-point ordinal scale: 3 - excellent, 2 - minor artifacts but diagnostic, 1 - artifacts rendering vessel evaluation incomplete.The mean heart rate of the patients was not significantly different between the SSCT scanner (61.1 bpm) and DSCT scanner (61.6 bpm). The mean kV for CTA was 101.4 on the SSCT scanner and 74.2 on the DSCT scanner (p<0.0001). The mean radiation dose for cardiac CTA, measured as DLP, was 134.2 on the SSCT scanner, 53% higher than the 87.7 on the DSCT scanner (p=0.001). For the SSCT scanner, 32% and 37% of RCAs were non-diagnostic according to readers 1 and 2, compared to 3% and 2% for the DSCT scanner. For the LM, LAD, and LCX, the rate of non-diagnostic cases was 2-7% with the SSCT scanner and 0-1% with the DSCT scanner.Under otherwise unchanged external conditions, the switch from SSCT to DSCT scanner for cardiac CT resulted in a significant reduction in radiation dose by approximately 34%, along with a significant decrease in non-diagnostic examinations. · Switching from an SSCT to a DSCT scanner in an outpatient setting results in a significant dose reduction of approximately 34%.. · The number of artifact-related non-diagnostic examinations is significantly reduced when using a DSCT scanner with higher temporal resolution.. · Outpatient cardiac CTA can be performed with an average radiation dose well below 2 mSv using both SSCT and DSCT systems.. · Michaely HJ, Lueck M, van Rickeln M. Impact of Next-Generation Computed Tomography Scanners on Image Quality and Radiation Dose in Cardiac CT Outpatient Imaging. Rofo 2025; 197: 1433-1439.